Fierce Biotech June 6, 2024
Two major players are vying for women’s hearts, but it’s not as romantic as it sounds.
After Medtronic put forward a head-to-head study in April showing its transcatheter aortic valve replacement implant had fewer complications within one year among patients with a small aortic annulus—the fibrous ring where the artery connects to the heart’s left ventricle, and a group that primarily includes women—TAVR rival Edwards Lifesciences has now responded with five-year data demonstrating similar safety rates for its valve regardless of the size of a patient’s annulus or their sex.
Edwards’ analysis pulled together more than 1,350 patients from two of its PARTNER trials who received its Sapien 3 implant, including people who took the transcatheter route while having low...
Today's Sponsors
Today's Sponsor